Since the FDA approval of inebilizumab (Uplizna; Horizon) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), there have been several new post-hoc analyses from the N-MOmentum trial, including 2 presented at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, February 23-25, 2023, in San Diego, California. One analysis evaluated whether there was a correlation between the treatment and COVID infection risk and outcomes while the other investigated whether long-term B-cell depletion in patients being treated with inebilizumab affected the antibody levels from childhood vaccinations against measles, mumps, rubella, varicella-zoster and tetanus.3
At the forum, Bruce Cree, MD, PhD, MAS, FAAN, the clinical research director of the UCSF Multiple Sclerosis Center, sat down for an interview with NeurologyLive® to provide more detail on the findings presented. In addition, he shared his thoughts on what the results mean for patients with NMOSD in their health outcomes.
More coverage of ACTRIMS 2023:([ Ссылка ])
